Patents Assigned to Amgen
  • Publication number: 20190218279
    Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
    Type: Application
    Filed: January 11, 2019
    Publication date: July 18, 2019
    Applicant: AMGEN INC.
    Inventors: Neeraj Jagdish AGRAWAL, Irwin CHEN, Su CHONG, Bryna FUCHSLOCHER, Kevin GRAHAM, Agnes Eva HAMBURGER, Mark Leo MICHAELS, Christopher MOHR, Derek E. PIPER, Kenneth William WALKER, Zhulun WANG, Cen XU
  • Patent number: 10344041
    Abstract: Provided herein are novel polymorphic forms and co-crystals of a compound useful in the treatment, prevention, or amelioration of cancer. In particular, the invention provides polymorphs and co-crystals of 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, which is an inhibitor of c-Met.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: July 9, 2019
    Assignee: Amgen, Inc.
    Inventors: David Bauer, Matthew Bio, Melanie Cooke, Katrina W. Copeland, Matthew Peterson, Michele Potashman, Roman Shimanovich, Helming Tan
  • Patent number: 10344016
    Abstract: Bromotriazole intermediates are useful in the synthesis of agonists of the APH receptor.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: July 9, 2019
    Assignee: AMGEN INC.
    Inventors: Paul John Dransfield, Zice Fu, Julie Anne Heath, Jeffrey T. Mihalic, Vatee Pattaropong
  • Patent number: 10344765
    Abstract: A liquid formulation comprising a peptide agonist of the calcium sensing receptor and method of preparing and using the formulation are provided.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: July 9, 2019
    Assignee: Amgen Inc.
    Inventors: Derek Maclean, Qun Yin
  • Patent number: 10344060
    Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: July 9, 2019
    Assignee: AMGEN INC.
    Inventors: Justin K. Murray, Jerry Ryan Holder, Malgorzata Wanska, Christopher M. Tegley, James R. Falsey, Elizabeth M. Doherty, Leslie P. Miranda, Kaustav Biswas, Bin Wu, Kelvin Sham, Jason C. Long
  • Publication number: 20190201412
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: March 11, 2019
    Publication date: July 4, 2019
    Applicant: AMGEN INC.
    Inventors: Sean P. Brown, Kexue Li, Yunxiao Li, Markian M. Stec
  • Patent number: 10336820
    Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: July 2, 2019
    Assignee: Amgen Inc.
    Inventors: Thomas Charles Boone, Jonathan Daniel Oliner, Eunkyung Lee
  • Publication number: 20190192628
    Abstract: This disclosure provides polypeptides comprising an antibody Fc region having a deletion of one or more cysteine residues in the hinge region and substitution with a sulfhydryl-containing residue of one or more CH3-interface amino acids. Also, provided are Fc-fusion proteins and antibodies containing said polypeptides, nucleic acids and vectors encoding said polypeptides, along with host cells and methods for making said polypeptides.
    Type: Application
    Filed: March 8, 2019
    Publication date: June 27, 2019
    Applicant: AMGEN INC.
    Inventors: Gunasekaran KANNAN, Jennifer LAVALLEE, Frederick W. JACOBSEN
  • Patent number: 10328062
    Abstract: The present invention relates to methods of therapeutic treatment of cancer using selective tyrosine kinase inhibitors and cancer biomarkers, such as MET amplification and high Met expression for patient selection.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: June 25, 2019
    Assignee: Amgen, Inc.
    Inventors: Sean Caenepeel, Angela Coxon, Zhiqiang Du, Paul Hughes, Robert Loberg, Gataree Ngarmchamnanrith, Beate Sable
  • Publication number: 20190183931
    Abstract: Antigen binding molecules, chimeric receptors, and engineered immune cells to FLT3 are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the FLT3 antigen binding molecules and engineered immune cells.
    Type: Application
    Filed: March 31, 2017
    Publication date: June 20, 2019
    Applicants: AMGEN INC., KiTE Pharma, Inc.
    Inventors: BAKKER Alice, WU Lawren, ARVEDSON Tara, WILTZIUS J. Jed, RODRIGUEZ Alvarez Ruben
  • Patent number: 10314976
    Abstract: An injector may include a container having a wall with an interior surface and a seal assembly with an interior surface, the interior surfaces of the wall and the seal assembly defining a closed sterile reservoir filled with a drug product. The injector may also include a fluid delivery system comprising a clean, unsheathed, rigid container needle having a point disposed only partially through the seal assembly in a storage state, and disposed through the interior surface of the seal assembly into the sterile reservoir in a delivery state. Further, the injection may include an actuator that is adapted to move the container needle from the storage state to the delivery state.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: June 11, 2019
    Assignee: AMGEN INC.
    Inventors: Francisca Tan-Malecki, Ronald Forster, Scott M. Nunn, Mark D. Holt, Son C. Tran, Sheldon Moberg
  • Publication number: 20190169259
    Abstract: The invention provides novel BTNL3 proteins, including multimers, fragments, fusion proteins, and variants. In addition, antibodies that can bind to BTNL3 proteins and nucleic acids encoding BTNL3 proteins are provided. Methods of making BTNL3 proteins using such nucleic acids are also provided. Uses for BTNL3 proteins, and agonists or antagonists thereof, are described.
    Type: Application
    Filed: January 24, 2019
    Publication date: June 6, 2019
    Applicant: Amgen Inc.
    Inventors: Heather ARNETT, Sabine Schadow ESCOBAR, Ryan Michael SWANSON, Joanne Louise VINEY
  • Publication number: 20190167908
    Abstract: Components of drug delivery devices can experience large impact forces by a spring-loaded drive mechanism causing a drug reservoir of the delivery device to fracture. For an autoinjector having a reservoir, a plunger rod, a drive mechanism, and a carrier that experiences two impact events when the autoinjector is activated, the mass of the carrier and the mass of the rod is increased by a mass multiplier to reduce the impact pressure at both first and second impacts. The internal pressure of the device decreases in relation to a mass of the impact system 110 to force ratio, where the force is the drive force of the drive mechanism. To reduce the impact pressure from the first event, the mass of the plunger rod may be increased within a range such that the ratio of plunger rod mass to drive force is within a range of approximately a value greater than 0 kg/kgf to approximately 0.05 kg/kgf.
    Type: Application
    Filed: May 15, 2017
    Publication date: June 6, 2019
    Applicant: AMGEN INC.
    Inventors: Sean Fitzgibbon, Julian Jazayeri
  • Publication number: 20190167682
    Abstract: The present invention provides compounds of Formula (I), as defined in the specification, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders, cough, or itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Application
    Filed: July 20, 2017
    Publication date: June 6, 2019
    Applicant: AMGEN INC.
    Inventors: Matthew WEISS, John R. BUTLER, Benjamin Charles MILGRAM, Gwenaella RESCOURIO, Alessandro BOEZIO, Brian Andrew SPARLING, Daniel LA
  • Patent number: 10307483
    Abstract: The invention relates to the formulation of pharmaceutical compositions of etanercept. The invention also relates to methods of removing buffer and of formulating pharmaceutical compositions of etanercept.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: June 4, 2019
    Assignee: AMGEN INC.
    Inventors: Monica Goss, Nicole Ball
  • Patent number: 10308704
    Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: June 4, 2019
    Assignee: Amgen Inc.
    Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Mark Leo Michaels, Thomas Charles Boone, Rohini Deshpande, Yue-Sheng Li, Huiquan Han
  • Patent number: 10301391
    Abstract: The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to BCMA, a second domain binding to an extracellular epitope of the human and/or the Macaca CD3? chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: May 28, 2019
    Assignees: AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC.
    Inventors: Tobias Raum, Markus Münz, Johannes Brozy, Peter Kufer, Patrick Hoffmann, Matthias Friedrich, Benno Rattel, Pamela Bogner, Andreas Wolf, Cornelius Pompe
  • Patent number: 10300075
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: May 28, 2019
    Assignee: AMGEN INC.
    Inventors: Sean P. Brown, Kexue Li, Yunxiao Li, Markian M. Stec
  • Patent number: D851754
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: June 18, 2019
    Assignee: AMGEN INC.
    Inventors: Margaux Frances Boyaval, Sigrid Moeslinger, Masamichi Udagawa
  • Patent number: D854146
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: July 16, 2019
    Assignee: AMGEN INC.
    Inventors: Brian Stonecipher, Ryan Jerome Ramos, Christian Plambech, Claus Jepsen, Emil Wegger Jensen